WinSanTorâs mission is simple-develop a drug that works. We recognize that there are no treatments for this disease today. Thus, WinSanTor is striving to impact the lives of todayâs patients heavily burdened by peripheral neuropathy. We are impatient. We are exploiting every strategy, mechanism, and regulation to accelerate approval of our drugs, including recycling a previously approved safe drug. Phase 1 is complete and we are now starting phase 2. Our goal is to get drug approval in the US by 2021 and perhaps sooner elsewhere. By focusing on patient impact rather than the bottom line, we believe weâre creating a new sustainable model for pharma companies based on patient need, not just money. Source
No articles found.
Smilelove offers clear aligner treatments direct-to-consumer: no expensive appoint...
Smilelove offers clear aligner treatments direc...
Nature is full of untapped potential. Microbes are a proven but underused resource...
Nature is full of untapped potential. Microbes ...
Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developi...
Eloxx Pharmaceuticals, Inc. is a clinical-stage...
Established in 2007, and headquartered in Wakefield, Massachusetts, Innovation Pha...
Established in 2007, and headquartered in Wakef...
Neurocarrus is developing a breakthrough therapy ( N-001 ) to fulfill the unmet ne...
Neurocarrus is developing a breakthrough therap...
Marinus Pharmaceuticals, Inc. is committed to improving the lives of patients suff...
Marinus Pharmaceuticals, Inc. is committed to i...
Forward Pharma A/S is a Danish biopharmaceutical company that commenced developmen...
Forward Pharma A/S is a Danish biopharmaceutica...
Join the National Investor Network and get the latest information with your interests in mind.